Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023

Black Diamond Therapeutics, Inc.

Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).
Cash, cash equivalents and investments $122.8M as of Dec 31, 2022; sufficient into Q3 2024.
Phase 1 update for EGFR inhibitor BDTX-1535 expected H2 2023; trial actively recruiting.
FDA cleared IND for BRAF/RAS inhibitor BDTX-4933; Phase 1 start expected H1 2023.
Spinout of Launchpad Therapeutics with $30M Series A led by Versant and NEA; BDTX retains minority stake.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Black Diamond Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 9, 2023, Black Diamond Therapeutics, Inc. announced its financial results for the year and three months ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001701541-23-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.